Key facts
- AQ Biotech’s last known valuation is $11.5M (Apr 2025).
- It has raised $8.6M; the latest was Angel (individual) ($2.4M) in Apr 2025.
- Notable investors include Tekes, Corporatum, Keksintösäätiö, Newentures.
- Status: Privately Held (backing).
Investors
4- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for AQ Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for AQ Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AQ Biotech
Developer of a non-invasive health screening and monitoring system designed for early detection of various diseases, particularly urinary tract cancers, starting from prostate cancers. The company's system is responsible for the early detection of oral and prostate cancers along with gastroenterological and infectious diseases as the enhanced TRF (transfer of funds) method provides a quick, accurate, and affordable process for the analysis of biological samples, enabling doctors to have access to non-invasive screening tests for preventive healthcare.
- Sector
- Healthcare
- HQ
- Turku, Finland
- Founded
- 2017
- Employees
- 10
- Website
- aqbiotech.com/
- Ownership
- Privately Held (backing)
AQ Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AQ Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AQ Biotech in its N-PORT filings yet. We sweep new filings monthly.